KR840001138A - 설포닐우레아의 제조방법 - Google Patents

설포닐우레아의 제조방법 Download PDF

Info

Publication number
KR840001138A
KR840001138A KR1019820003918A KR820003918A KR840001138A KR 840001138 A KR840001138 A KR 840001138A KR 1019820003918 A KR1019820003918 A KR 1019820003918A KR 820003918 A KR820003918 A KR 820003918A KR 840001138 A KR840001138 A KR 840001138A
Authority
KR
South Korea
Prior art keywords
substituted
salt
carbon atoms
formula
group
Prior art date
Application number
KR1019820003918A
Other languages
English (en)
Other versions
KR880002706B1 (ko
Inventor
힛쨀 폴커 (외 3)
Original Assignee
하인리히 벡커, 베른하르트 벡크
훽스트 아크티엔 게젤샤프트
베른하르트 벡크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인리히 벡커, 베른하르트 벡크, 훽스트 아크티엔 게젤샤프트, 베른하르트 벡크 filed Critical 하인리히 벡커, 베른하르트 벡크
Publication of KR840001138A publication Critical patent/KR840001138A/ko
Application granted granted Critical
Publication of KR880002706B1 publication Critical patent/KR880002706B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

내용 없음

Description

설포닐우레아의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. a) 다음 일반식(Ⅱ)의 그룹으로 4위치에서 치환된 벤젠설포닐카밤산 유도체를 아민인 R2-NH2또는 이의 염과 반응시키거나 또는 다음 일반식(Ⅲ)의 설폰아미드 또는 이의 염을 R2에 의해 치환된 카밤산 유도체와 반응시키거나
  2. b) 다음 일반식(Ⅳ)의 그룹으로 치환된 벤젠-설포닐 이소우레아 에테르, -이소티오우레아 에테르, -파라반산 또는 -할로게노포름아미딘을 분해시키거나,
  3. c) 다음 일반식(Ⅴ)의 그룹으로 치환된 벤젠-설포닐티오우레아에서 황원자를 산소로 치환하거나
  4. d) 상응하게 치환된 벤젠설피닐-또는-설페닐우레아를 산화시키거나
  5. e) 공정단계에서 임의로, 다음 알반식(Ⅵ)의 그룹을 다음 일반식(Ⅶ)의 벤젠설포닐우레아로 도입시키고
  6. f) 상응하게 치환된 벤젠설포닐 할라이드를 R2-치환된 우레아 또는 이들 알카리금속염과 반응시키거나 또는 상응하게 치환된 벤젠설피닐 할라이드 또는 산축합제 존재하에, 상응하게 치환된 설핀산 또는 이들 알카리금속염을 N-R2-N1-하이드록시우레아와 반응시키거나, 임의로 수득된 염을 유리화합물로 전환시키거나 또는 임의로 염을 형성시키기 위해 알카리 시약으로 반응생성물을 처리함을 포함하는 다음 일반식(I)의 설포닐우레아 및 생리학적으로 허용되는 염의 제조방법.
  9. 상기 일반식에서, Y는 탄소수 2내지 3의 알킬렌을 나타내고, R은 탄소수 1내지 4의 알킬을 나타내고, R4은 수소, 염소 또는 메틸을 나타내고, R2는 탄소수 3내지 6의 알킬, 시클로알킬, 알킬시클로알킬, 시클로알킬알킬, 시클로알케닐, 알킬시클로알케닐 또는 시클로알케닐알킬(각기 탄소수 5내지 8을 함유함)을 나타낸다.
  10. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR8203918A 1981-09-02 1982-08-31 설포닐 우레아의 제조방법 KR880002706B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3134780.0 1981-09-02
DE19813134780 DE3134780A1 (de) 1981-09-02 1981-09-02 "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
DEP3134780.0 1981-09-02

Publications (2)

Publication Number Publication Date
KR840001138A true KR840001138A (ko) 1984-03-28
KR880002706B1 KR880002706B1 (ko) 1988-12-26

Family

ID=6140704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR8203918A KR880002706B1 (ko) 1981-09-02 1982-08-31 설포닐 우레아의 제조방법

Country Status (20)

Country Link
US (1) US4542139A (ko)
EP (1) EP0073507B1 (ko)
JP (1) JPS5846068A (ko)
KR (1) KR880002706B1 (ko)
AT (1) ATE16102T1 (ko)
AU (1) AU558339B2 (ko)
CA (1) CA1193603A (ko)
DE (2) DE3134780A1 (ko)
DK (1) DK391982A (ko)
ES (6) ES8306118A1 (ko)
FI (1) FI76567C (ko)
GR (1) GR76895B (ko)
HU (1) HU188805B (ko)
IL (1) IL66697A0 (ko)
MX (1) MX154808A (ko)
NO (1) NO822940L (ko)
NZ (1) NZ201768A (ko)
PH (1) PH18218A (ko)
PT (1) PT75492B (ko)
ZA (1) ZA826391B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3210063A1 (de) * 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
US5681832A (en) * 1995-02-17 1997-10-28 The United States Of America As Represented By The Department Of Health And Human Services Aroylaniline compounds, pharmaceutical compositions, and methods of using same to inhibit viral activity
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
CA2433158C (en) * 2000-12-28 2011-05-10 Shionogi & Co., Ltd. Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
ATE540034T1 (de) * 2005-11-03 2012-01-15 Portola Pharm Inc Ä4-(6-halo-7-substituierte-2,4-dioxo-1,4-dihydr - 2h-chinazolin-3-yl)-phenylü-5-chloro-thiophen-2 yl-sulfonylharnstoffe und relevante formen und verfahren
EP2076510A2 (en) * 2007-05-02 2009-07-08 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof, and formulations thereof, for the treatment of thrombosis and trombosis related conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819633A (en) * 1970-04-01 1974-06-25 Erba Carlo Spa (iso)quinolyl sulfonylureas having antidiabetic activity
AT357560B (de) * 1976-05-18 1980-07-25 Hoechst Ag Verfahren zur herstellung von neuen (1,2- dihydro-2-oxo-nicotinamido)-alkylbenzolsul- fonylharnstoffen und von deren salzen
DE2621958A1 (de) * 1976-05-18 1977-12-08 Hoechst Ag Benzolsulfonylharnstoffe und verfahren zu ihrer herstellung
MTP848B (en) * 1978-06-27 1980-06-24 Hoechst Ag Sulfonyl ureas process for their manufacture pharmaceutical preparation on the basis of there compounds and their use
DE2948434A1 (de) * 1979-12-01 1981-06-11 Hoechst Ag, 6000 Frankfurt 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung
DE2951135A1 (de) * 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung

Also Published As

Publication number Publication date
AU8789282A (en) 1983-03-10
IL66697A0 (en) 1982-12-31
KR880002706B1 (ko) 1988-12-26
ES515397A0 (es) 1983-05-01
GR76895B (ko) 1984-09-04
NO822940L (no) 1983-03-03
DE3266953D1 (en) 1985-11-21
ES8306117A1 (es) 1983-05-01
FI823007L (fi) 1983-03-03
ES8306116A1 (es) 1983-05-01
ES515396A0 (es) 1983-05-01
ES515398A0 (es) 1983-05-01
US4542139A (en) 1985-09-17
DE3134780A1 (de) 1983-03-10
ATE16102T1 (de) 1985-11-15
EP0073507A1 (de) 1983-03-09
PH18218A (en) 1985-04-30
AU558339B2 (en) 1987-01-29
ES515384A0 (es) 1983-05-01
ES515395A0 (es) 1983-05-01
DK391982A (da) 1983-03-03
PT75492A (de) 1982-10-01
ES8306113A1 (es) 1983-05-01
EP0073507B1 (de) 1985-10-16
ES515399A0 (es) 1983-05-01
ES8306115A1 (es) 1983-05-01
FI76567B (fi) 1988-07-29
JPS5846068A (ja) 1983-03-17
NZ201768A (en) 1985-03-20
FI823007A0 (fi) 1982-08-31
ZA826391B (en) 1983-07-27
ES8306118A1 (es) 1983-05-01
PT75492B (de) 1985-05-31
FI76567C (fi) 1988-11-10
ES8306114A1 (es) 1983-05-01
CA1193603A (en) 1985-09-17
MX154808A (es) 1987-12-15
HU188805B (en) 1986-05-28

Similar Documents

Publication Publication Date Title
KR870003998A (ko) 퀴나졸린 유도체류의 제조방법
KR840000528A (ko) 비스-트리아졸 유도체의 제조방법
KR840001169A (ko) 항비루스성 화합물의 제조방법
KR870010015A (ko) 페닐-피페라진 유도체 및 그의 제조방법
KR840001149A (ko) N-페닐설포닐-n'-피리미디닐- 및 -트리아지닐-우레아의 제조방법
KR840001138A (ko) 설포닐우레아의 제조방법
KR860000243A (ko) 아민유도체의 제조방법
KR850008667A (ko) 벤즈 아제핀 유도체의 제조방법
KR860001064A (ko) β-락탐 화합물의 제조방법
KR870006082A (ko) 10β-알키닐에스트렌 유도체의 제조방법
KR860000287A (ko) 8-알킬티오-2-피페라지노-피리미도[5,4-d]피리미딘 및 이의 산부가염의 제조방법
KR840003615A (ko) 피리딘 화합물의 제조방법
KR840005125A (ko) 치환된 벤조일-(티오)우레아의 제조방법
KR840004081A (ko) 설포닐 우레아의 제조방법
ATE61577T1 (de) Fluorierte abkoemmlinge von vitamin-d3 und verfahren zu deren herstellung.
ES8602621A1 (es) Procedimiento de preparacion de derivados del acido carbami-co
KR880011103A (ko) 5-아미노-4,6-디할로게노피리딘의 제조방법
HUT45518A (en) Process for producing 1,5-benzothiazepine derivatives and pharmaceutics comprising these compounds
KR830005191A (ko) 푸란유도체의 제조방법
KR840004103A (ko) 디아졸릴 알칸올의 제조방법
KR890009884A (ko) 신규 방법
KR850008160A (ko) 이미다졸 유도체의 제조방법
KR880000401A (ko) 벤조일 우레아의 제조방법
KR850005418A (ko) 설포닐구아니딘 유도체의 제조방법
KR830004296A (ko) 벤젠설포닐 우레아의 제조방법